Overview

A Study to Evaluate the Safety, Tolerability, PK and PD of HNC364 Injectable Suspension

Status:
Recruiting
Trial end date:
2023-04-05
Target enrollment:
Participant gender:
Summary
This is a non-randomized, dose-escalation first-in-human study to evaluate the safety, tolerability, PK, and PD of HNC364 following intramuscular administration of single ascending doses.
Phase:
Phase 1
Details
Lead Sponsor:
Guangzhou Henovcom Bioscience Co. Ltd.